Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William B...
July 08 2021 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that it will release its second
quarter 2021 financial results and operational highlights before
open of U.S. markets on Thursday, August 5, 2021.
Management will host a conference call and
webcast at 8:30 am EDT/1:30 pm GMT to discuss the company’s
financial results and provide a general business update. To listen
to the webcast and view the accompanying slide presentation, please
go to the events section of Autolus’ website.
The call may also be accessed by dialing (866)
679-5407 for U.S. and Canada callers or (409) 217-8320 for
international callers. Please reference conference ID 9757293.
After the conference call, a replay will be available for one week.
To access the replay, please dial (855) 859-2056 for U.S. and
Canada callers or (404) 537-3406 for international callers. Please
reference conference ID 9757293.
Additionally, Christian Itin, CEO of Autolus,
will participate in a panel discussion titled “Cell Therapies In
the Next Decade” to be held on Wednesday, July 14, at 08.55 a.m.
EDT at the William Blair Biotech Focus Conference 2021, taking
place virtually from July 14-15, 2021. The company will also host
virtual one-on-one meetings at the conference. The live panel
discussion can be viewed from the investor section of the Autolus
website and will be available for a period of 30 days after the
conference.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhDVice President, Business
Strategy and Planning+44 (0) 7587 372
619l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Sep 2023 to Sep 2024